CANCER IMMUNOLOGY

项目概述（见说明）：癌症免疫学项目由来自13个部门的34名研究人员（29名正式成员和5名准成员）组成。该计划的总体目标是了解免疫细胞在生理和病理条件下如何工作，以便开发新的策略来利用免疫系统的力量来对抗癌症，并了解淋巴细胞生物学的独特方面如何促进肿瘤的发生。具体目标是：1)发现导致免疫系统恶性肿瘤的机制，并开发利用免疫细胞恶性肿瘤的特异性生物学的靶向治疗；2)研究肿瘤宿主免疫应答及其改变的基本机制，包括抗原呈递、信号传导、效应程序和耐受等方面；3)开发新的治疗癌症的免疫疗法，并在临床前和临床研究中进行测试。为了实现这些目标，该计划促进了实验室科学家和临床医生之间的互动论坛，他们对癌症免疫学有共同的兴趣；提供获得个别实验室无法获得的尖端技术的机会；并支持会员，特别是初级研究人员，为癌症免疫学转化应用的试点项目提供种子资金。Drs。Sandra Demaria和Michael Dustin是这个项目的共同负责人。自上次竞争性申请以来，总资金从12,703,949美元增加到15,514,219美元。成员从38个减少到34个。这一期间共有333份出版物，其中7.5%是方案内合作，20.1%是方案间合作，5.4%是方案内和方案间合作

PROJECT SUMMARY (See instructions): The Cancer Immunology Program is composed of 34 investigators (29 Full and 5 Associate members) from 13 Departments. The overall goal of the Program is to understand how immune cells work in physiological and pathological conditions, in order to develop new strategies to harness the power of the immune system to fight cancer, and to understand how unique aspects of lymphocyte biology contribute to oncogenesis. The specific aims are: 1) To discover mechanisms that lead to malignancies of the immune system and develop targeted therapies that exploit the urtique biology of immune cell malignancies; 2) To study the basic mechanisms regulating immune responses and their alteration in tumor-bearing hosts, including aspects of antigen presentation, signaling, effector programs and tolerance; and 3) To develop new immunotherapies for the treatment of cancer and test them in pre-clinical and clinical studies. To achieve these goals, the Program promotes forums for interactions between laboratory scientists and clinicians who share a common interest in Cancer Immunology; provides access to sophisticated technologies that are beyond the reach of individual laboratories; and supports members, particularly junior investigators, with seed money for pilot projects for translational applications in cancer immunology. Drs. Sandra Demaria and Michael Dustin are the Co-Leaders for this Program. Total funding increased from $12,703,949 to $15,514,219 since the last competitive application. Membership has decreased from 38 to 34. Publications for the period total 333, of which 7.5% are intra-programmatic, 20.1% are inter-programmatic, and 5.4% are both intra- and inter-programmatic collaborations